Results 201 to 210 of about 6,454 (219)
People With Lowest Physical Functioning Scores Showed Greatest Improvement After Tirzepatide Treatment. [PDF]
Obesity (Silver Spring)Li X +7 more
europepmc +1 more source
Tirzepatide as a Potential Disease-Modifying Therapy in Lipedema: A Narrative Review on Bridging Metabolism, Inflammation, and Fibrosis. [PDF]
Int J Mol SciViana DPDC, Invitti AL, Schor E.
europepmc +1 more source
Acute Mesenteric Ischemia as a Severe Complication Associated With Tirzepatide: A Case Report and Safety Alert. [PDF]
CureusBrooks S +9 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Reactions Weekly
In this column, Sharon Rees aims to refresh knowledge and interest in some of the commonly used drugs in a series of posts on X. This month she is talking about #tirzepatide
+32 more sources
In this column, Sharon Rees aims to refresh knowledge and interest in some of the commonly used drugs in a series of posts on X. This month she is talking about #tirzepatide
+32 more sources
Reactions Weekly, 2023
ABSTRACT Obesity affects a large percentage of patients in the United States and is associated with increased mortality and higher healthcare costs. Newer guidelines recommend a minimum of 10% weight loss goal for patients with obesity, and medical management options fall short.
Christine G, Niedbala, Roxanne, Sprague
+8 more sources
ABSTRACT Obesity affects a large percentage of patients in the United States and is associated with increased mortality and higher healthcare costs. Newer guidelines recommend a minimum of 10% weight loss goal for patients with obesity, and medical management options fall short.
Christine G, Niedbala, Roxanne, Sprague
+8 more sources
Hospital Pharmacy, 2022
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Danial E. Baker +2 more
openaire +2 more sources
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing
Danial E. Baker +2 more
openaire +2 more sources
Drugs, 2022
Tirzepatide (Mounjaro™) is a single molecule that combines dual agonism of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Native GIP and GLP-1 are incretin hormones that stimulate insulin secretion and decrease glucagon secretion.
openaire +2 more sources
Tirzepatide (Mounjaro™) is a single molecule that combines dual agonism of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Native GIP and GLP-1 are incretin hormones that stimulate insulin secretion and decrease glucagon secretion.
openaire +2 more sources